GlassScriptPhysician profile
Anna M Magat
NPI 1346276193
$12,523.49
in general payments reported to CMS, 2019-2025
38 companies · $2,106 in 2025
The $2,106 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,349 · 2020: $1,268 · 2021: $2,224 · 2022: $1,536 · 2023: $1,595 · 2024: $1,446 · 2025: $2,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,077 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,076.91 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,168.01 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,749.95 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,714.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,278.59 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $795.96 | 2019-2025 | Ofev, Jardiance |
| Abbvie INC. | $655.47 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $578.85 | 2019-2022 | |
| Pfizer INC. | $488.21 | 2019-2025 | |
| Astellas Pharma US INC | $426.31 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $410.60 | 2019-2025 | Otezla, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $211.30 | 2019-2022 | |
| Exact Sciences Corporation | $200.97 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $192.65 | 2019-2020 | |
| Abbott Laboratories | $183.46 | 2021-2022 | |
| Amarin Pharma, INC. | $166.96 | 2019-2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Magat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.